Treatment of Relapsed/Refractory Mantle Cell Lymphoma

Opinion
Video

Pallawi Torka, MD, and the Oncology Brothers discuss the therapeutic landscape for patients with relapsed/refractory mantle cell lymphoma.

Recent Videos
Patients with mantle cell lymphoma who are older and have less fitness may be eligible for regimens that include bendamustine/rituximab.
It may be critical to sequence BCL-2 inhibitors with BTK inhibitors for patients with mantle cell lymphoma in the relapsed/refractory setting.
Reducing the manufacturing time of CAR T-cell therapy may have a big impact on the treatment of patients with mantle cell lymphoma.
Related Content